Streetbeat News

Analyst Ratings

OPGN

HC Wainwright & Co. analyst Yi Chen has downgraded OpGen (NASDAQ:OPGN) from Buy to Neutral.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:42 am

IRON

HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Disc Medicine (NASDAQ:IRON) and raises the price target from $66 to $70.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:40 am

ALIM

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Alimera Sciences (NASDAQ:ALIM) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:39 am

KPRX

HC Wainwright & Co. analyst Yi Chen maintains a 'Buy' rating on Kiora Pharmaceuticals (NASDAQ:KPRX), but has lowered the price target from $7 to $2.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:38 am

ASLN

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on ASLAN Pharma (NASDAQ:ASLN) and maintained a price target of $17.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:37 am

CASI

HC Wainwright & Co. analyst Sean Lee has reiterated a 'Buy' rating on CASI Pharmaceuticals and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:36 am

PSTV

HC Wainwright & Co. analyst Sean Lee has reiterated a 'Buy' rating on Plus Therapeutics (NASDAQ:PSTV) and maintained an $8 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:35 am

RWLK

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on ReWalk Robotics (NASDAQ:RWLK) and maintained a $3 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:34 am

RANI

HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on Rani Therapeutics Hldgs (NASDAQ:RANI) but lowers the price target from $22 to $20.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:33 am

MGNI

Needham analyst Laura Martin has reiterated a 'Buy' rating on Magnite (NASDAQ:MGNI) and maintained a price target of $15.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:32 am